BioPharmX – Protocol BPX -01-C04- BPX-[ADDRESS_1078792] OF 1 AND 2% BPX -01 MINOCYCLINE TOPI[INVESTIGATOR_784325] -NODULAR  ACNE 
VULGARIS  
 
PROTOCOL  # BPX -01-C04 
 
 
VERSION  4.0 
06 July 2017  
 
Medical  Monitor  
 
Sponsor:  BioPharmX,  Inc. 
[ADDRESS_1078793], Suite D 
Menlo  Park,  CA [ZIP_CODE],  [LOCATION_003] 
Tel: (650) 889 -5020  
 
Sponsor  Representative:  AnnaMarie  Daniels  
Executive Vice President 
Clinical  & Regulatory  Affairs  

BioPharmX – Protocol BPX -01-C04- BPX-[ADDRESS_1078794] OF ABBREVIATIONS  ................................ ................................ ................................ .........  9 
SUMMARY  ................................ ................................ ................................ ................................ .. 10 
1 BACKGROUND  ................................ ................................ ................................ .....................  16 
1.1 Acne  Vulgaris  ................................ ................................ ................................ ...................  16 
1.2 BPX -01 Minocycline  in Acne  Vulgaris  ................................ ................................ ...........  16 
1.3 Rationale  for this Study  ................................ ................................ ................................ .... 17 
2 STUDY HYPOTHESIS AND OBJECTIVE(S)  ................................ ................................ ..... 18 
2.1 Hypothesis  ................................ ................................ ................................ ........................  18 
2.2 Objectives  ................................ ................................ ................................ .........................  18 
3 STUDY ENDPOINTS  ................................ ................................ ................................ ............  19 
3.1 Primary  Endpoint  ................................ ................................ ................................ .............  19 
3.2 Secondary  and Exploratory  Endpoints  ................................ ................................ .............  19 
4 STUDY DESIGN  ................................ ................................ ................................ ....................  20 
5 STUDY POPULATION  ................................ ................................ ................................ .........  21 
5.1 Inclusion  Criteria  ................................ ................................ ................................ ..............  21 
5.2 Exclusion  Criteria  ................................ ................................ ................................ .............  22 
5.3 Discontinuations  ................................ ................................ ................................ ...............  23 
6 TREATMENT  ................................ ................................ ................................ .........................  25 
6.1 Treatment  Administered  ................................ ................................ ................................ ... 25 
6.2 Study  Treatment  ................................ ................................ ................................ ...............  25 
6.2.1 Description  ................................ ................................ ................................ ................  25 
6.2.2 Storage  Conditions  ................................ ................................ ................................ .... 25 
6.2.3 Study  Drug Dispensing  and Return  ................................ ................................ ...........  26 
6.2.4 Drug  Accountability  ................................ ................................ ................................ .. 26 
6.2.5 Method  of Assignment  to Treatment ................................ ................................ ..........  26 
6.2.6 Rationale  for Selection and  Timing  of Doses  in the Study  ................................ ........  26 
6.2.7 Assessment  of Treatment  Compliance  ................................ ................................ ....... 27 
6.3 Concomitant  Therapy  ................................ ................................ ................................ ....... 27 
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 3 of 47  6.3.1 Permitted  Therapi[INVESTIGATOR_014]  ................................ ................................ ................................ .. 27 
6.3.2 Prohibited  Therapi[INVESTIGATOR_784326]  ................................ ................................ .........  28 
7 SCHEDULE OF EVENTS  ................................ ................................ ................................ ..... 30 
8 STUDY ASSESSMENTS  ................................ ................................ ................................ ....... 32 
8.1 Efficacy  Assessments  ................................ ................................ ................................ ....... 32 
8.1.1 Acne  Lesion  Counts  ................................ ................................ ................................ ... 32 
8.1.2 Investigator  Global  Assessment  (IGA)  ................................ ................................ ...... 33 
8.1.3 Patient -Reported  Outcomes  (PROs)  ................................ ................................ .........  33 
[IP_ADDRESS]  Patient  Global  Impression  of Severity  (PGI -S) ................................ ......................  33 
[IP_ADDRESS]  Patient  Global  Impression  of Improvement  (PGI -I) ................................ ..............  34 
8.1.4 Photographic  Documentation  ................................ ................................ ...................  35 
8.2 Safety  Assessments  ................................ ................................ ................................ ..........  35 
8.2.1 Vital  Signs  ................................ ................................ ................................ .................  35 
8.2.2 Brief  Physical  Examination  ................................ ................................ .......................  35 
8.2.3 Clinical  Laboratory  Tests  ................................ ................................ ..........................  35 
8.2.4 Cutaneous  Tolerance  Scores  ................................ ................................ .....................  36 
8.2.5 Incidence  of Minocycline -Induced  Skin  Hyperpi[INVESTIGATOR_371],   Visual  
Disturbances/Headaches  Suggestive  of Pseudotumor  Cerebri  ................................ .............  [ADDRESS_1078795]  Disposition  ................................ ................................ ................................ .. 42 
10.2.3  Efficacy  Analysis  ................................ ................................ ................................ ..... 42 
[IP_ADDRESS]  Primary  Analysis  ................................ ................................ ................................ .. 42 
[IP_ADDRESS]  Secondary  and Exploratory  Analyses  ................................ ................................ .. 43 
[IP_ADDRESS]  Safety  Analysis ................................ ................................ ................................ ...... 43 
10.2.4  Interim  Analysis  ................................ ................................ ................................ ...... 44 
11 DATA  QUALITY  ASSURANCE/SITE  MONITORNG  ................................ .....................  [ADDRESS_1078796]  RECORDS  ...............  45 
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 4 of 47  14 INVESTIGATOR’S  FILES AND  RETENTION OF DOCUMENTS  ................................ . 45 
15 ETHICS  ................................ ................................ ................................ ................................ . 45 
15.1 Local  Regulations/Declaration  of Helsinki  ................................ ................................ .... 46 
15.2 Ethical  Review  ................................ ................................ ................................ ...............  46 
15.3 Informed  Consent  ................................ ................................ ................................ ...........  46 
16 PUBLICATION  POLICY  ................................ ................................ ................................ ..... 46 
17 REFERENCES  ................................ ................................ ................................ ......................  47 
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 5 of 47   
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 6 of 47  SIGNATURE  [CONTACT_759457], and provide 
the necessary assurances that this trial will be conducted according to local legal and regulatory 
requirements and all applicable U.S. federal regulations, and ICH guidelines.  
 
 
Sponsor  Approval:  
 
 
AnnaMarie  Daniels  
Executive  Vice  President,  Clinical  & 
Regulatory Affairs  
BioPharmX,  Inc. 10-Aug-2017 
 
Date  (DD-MMM -YYYY  

BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 7 of 47  Institution  Name  [CONTACT_784371]  (DD-MMM -YYYY)  
   
 
 
By [CONTACT_27616],  I agree  to personally  supervise  the conduct  of this study  at my study  site and to 
ensure its conduct is in compliance with the protocol, informed consent, Institutional Review Board 
(IRB)/Independent Ethics Committee (IEC) procedures, instructions from BioPharmX and their 
representatives, the Declaration of Helsinki, International Conf erence on Harmonization (ICH) Good 
Clinical Practices Guidelines, U.S. federal regulations, and local regulations governing the conduct of 
clinical studies.  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 8 of 47   
BioPharmX – Protocol BPX -01-C04- BPX-[ADDRESS_1078797]  OF ABBREVIATIONS  
 
AE Adverse  Event/Adverse  Experience  
ALT  Alanine  Aminotransferase  
AST Aspartate  Aminotransferase  
-hCG -Human  Chorionic  Gonadotropin  
BMI Body  Mass Index  
bpm Beats  Per Minute  
BSA  Body  Surface  Area  
BUN  Blood  Urea  Nitrogen  
CK Creatinine  Kinase  
CRF Case  Report  Form  
CK Creatine  Kinase  
eCRF  Electronic  Case  Report  Form  
ET Early  Termination  
FDA  Food  and Drug Administration  
FSH Follicle -Stimulating  Hormone  
GCP  Good  Clinical  Practice  
GGT  Gamma -Glutamyl  Transferase  
HCT  Hematocrit  
HGB  Hemoglobin  
HIPAA  Health  Insurance  Portability  and Accountability  Act of 1996  
ICH International  Conference  on Harmonization  
IGA Investigator’s  Global  Assessment  
IRB Institutional  Review  Board  
ITT Intent -To-Treat  Population  
LDH  Lactate  Dehydrogenase  
MCH  Mean  Corpuscular  Hemoglobin  
MCHC  Mean  Corpuscular  Hemoglobin  Concentration  
MCV  Mean  Corpuscular  Volume  
MIC Minimum  Inhibitory  Concentration  
OTC  Over -the-Counter  
PGI-I Patient  Global  Impression  of Improvement  
PGI-S Patient  Global  Impression  of Severity  
PP Per-Protocol  Population  
PRO  Patient -Reported  Outcome  
RBC  Red Blood  Cells  (count)  
REB  Research  Ethics  Board  
SAE Serious  Adverse  Event/Serious  Adverse  Experience  
SAP Statistical  Analysis  Plan 
SAF Safety  Population  
TEAEs  Treatment -Emergent  Adverse  Events  
WBC  White  Blood  Cells  (count)  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 10 of 47  SUMMARY  
Title:  An Open Label Study to Document the Treatment Effect of 1 and 2% 
BPX -01 Minocycline Topi[INVESTIGATOR_784327]-nodular Acne Vulgaris (Protocol Number BPX -01-C04)  
Phase:  2 
 
Population:  Up to 40 male or female subjects aged between 18 and 40 years with  
moderate to severe inflammatory non -nodular acne vulgaris will be 
included in this study.  
 
Number  of Sites:  Up to 4 investigational  sites will participate  in this multicenter  study.  
 
Study  Duration:    Overall  study duration  is expected  to be approximately  24 weeks 
(6 months). The study duration per subject is approximately 20 -24 weeks 
(including [ADDRESS_1078798] -
treatment follow -up to assess time to recurrence).  
 
Hypothesis:  BPX -[ADDRESS_1078799] s with moderate to severe 
inflammatory non -nodular acne vulgaris.  
 
Objectives:  
 
Primary:  
• To obtain photo -documentation of the efficacy of BPX -01 minocycline 1% or 2% topi[INVESTIGATOR_784328] -nodular acne vulgaris  
 
Secondary:  
• To evaluate  the cutaneous  tolerance  of BPX -01 minocycline  1% or 2% topi[INVESTIGATOR_784329]:  
 
Primary  Efficacy  Endpoint:  
• Change  from  baseline  in inflammatory  lesion  counts  at Week  12 
Secondary  Efficacy  Endpoint:  
• Change  from  baseline  in inflammatory  lesion  counts  at Weeks  1, 2, 4, and 8 
Exploratory  Efficacy  Endpoints:  
• Subjects  with at least a two-grade  reduction  in IGA at Week  12 
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 11 of 47  • Percent  change  from  baseline  in inflammatory  lesion  counts  at Weeks  1, 2, 4, 8, and 12 
• Absolute  change  and percent  change  from  baseline  in noninflammatory  lesion  counts  at 
Weeks 1, 2, 4, 8, and 12  
• Absolute change and percent change from baseline in total lesion counts at Weeks 1, 2, 4,  
8, and 12  
• Absolute change and percent change from baseline in the Investigator’s Global Assessment 
(IGA) at Weeks 1, 2, 4, 8, and 12  
• Proportion of subjects with an IG A of clear (0) or almost clear (1) at Weeks 1, 2, 4, 8, and 
12 
• Proportion  of subjects  with at least a two-grade  reduction  in IGA at Weeks  2, 4, and 8 
• Change from baseline in Patient Global Impression of Severity (PGI -S) at Weeks 1, 2, 4, 8, 
and 12  
• Patient  Global  Impression  of Improvement  (PGI -I) at Weeks  1, 2, 4, 8, and 12 
Safety  Endpoints:  
• Incidence  of treatment -emergent  adverse  events  (TEAEs)  
• Shift  from  baseline  in clinical  hematology  and chemistry  laboratory  tests 
• Change  from  baseline  in the cutaneous  tolerance  score  evaluated  by [CONTACT_63634] 
(erythema, scaling -peeling, edema)  
• Change from baseline in the cutaneous tolerance score evaluated by [CONTACT_423] (tightness, 
burning, stinging, itching)  
• Incidence  of visual  disturbances/headaches  suggestive  of pseudotumor  cerebri  and 
minocycline -induced skin hyperpi[INVESTIGATOR_371]  
• Incidence  of product  related  facial  staining  
 
Overall  Study  Design:  
 
This is a 12-week,  multi -center,  open  label,  two-arm study.  
 
Subjects will be assigned to treatment with 1% or 2% BPX -[ADDRESS_1078800] 30 minutes before bedtime each night for 12  weeks. 
Lesion counts, IGA, and Patient -Reported Outcomes (PGI -S and PG I-I) will be performed to 
assess efficacy. Photographs will be taken to document treatment effect.  
 
Safety will be assessed with the vital signs, brief physical examination, clinical laboratory tests, 
cutaneous tolerance score, incidence of minocycline -induced skin hyperpi[INVESTIGATOR_371], incidence 
of visual disturbances and/or headaches suggestive of pseudotumor cerebri, incidence of product 
related facial staining and collection of adverse events.  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 12 of 47  Inclusion  Criteria:  
 
Subjects  will be eligible  if they meet  all of the following  criteria  at the screening  and baseline 
(Day 0) visits, unless specified otherwise:  
 
1. Male or female subjects aged between [ADDRESS_1078801] at unacceptable risk or could in terfere with study 
assessments or integrity of the data.  
3. Moderate  to severe  inflammatory  non-nodular  acne vulgaris,  defined  as follows:  
a. IGA score  of 3 (moderate)  or 4 (severe)  at baseline  (Day  0); 
b. 20-60 inflammatory  lesions  on the face at baseline  (Day  0); 
c. 0-100 noninflammatory  lesions  on the face at baseline  (Day  0); 
d. Maximum  of 2 nodules  (≥ 5 mm)  on the face at baseline  (Day 0). 
4. Female subjects of childbearing potential (including pre -puberty) are willing to use 
effective contraceptive method for at lea st 28 days before baseline (Day 0) and at least  
[ADDRESS_1078802]  a sterilized  or same -sex partner 
for the duration of the study. Effective contraceptive methods are: systemic hormonal 
contraceptives, intrauterine device or barrier method of contraception in conjunction with 
spermicide, or agree to sexual abstinence. Hormonal contraceptives must be on a stable 
dose for at least 12 weeks before baseline (Day 0). Subjects using low dose oral 
contraceptives must use a second form of birth control (e.g., barrier method such as 
condoms with spermicide).  
Note:  Female  subjects  of nonchildbearing  potential  are defined  as follows:  
a. Female subjects who have had surgical sterilization (hysterectomy, bilateral 
oophorectomy, bilateral salpi[INVESTIGATOR_1656], or bilateral tubal ligation);  
b. Female subjects who have had a cessation of menses for at least 12 months and a 
follicle -stimulating hormone ( FSH) test confirming nonchildbearing potential 
(refer to the central laboratory reference range for menopausal women) or 
cessation of menses for at least 24 months without FSH levels confirmed;  
5. Female subjects of childbearing potential must have a negative urine pregnancy test at 
screening and baseline (Day 0).  
6. Treatment  with hormonal  therapy  must  be on a stable  dose and frequency  for at least 
12 weeks before baseline (Day 0) and must remain stab le throughout the study.  
7. Subjects who use make -up, facial moisturizers, creams, lotions, cleansers and/or 
sunscreens must have used the same product brands/types for a minimum period of 14 
days prior to baseline (Day 0), must agree not to change brand/type  or frequency of use 
throughout the study and must agree not to use make -up, facial moisturizers, creams, 
lotions, cleansers and/or sunscreens on the clinic visit days before the visit.  
8. Subjects must be capable of giving informed consent and the written in formed consent 
must be obtained prior to any study -related procedures.  
 
Exclusion  Criteria:  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 13 of 47  Subjects will not be eligible if they meet any of the following criteria at the screening or baseline 
(Day 0) unless specified otherwise:  
 
1. Female subj ect who is breastfeeding, pregnant or who is planning a pregnancy during the 
study.  
2. Have  acne fulminans  or conglobata,  or nodulocystic  acne.  
3. Have a history of skin disease, presence of skin condition, skin pi[INVESTIGATOR_784330], in the opi[INVESTIGATOR_871], would interfere with the study.  
4. Have a history of cancer or lymphoproliferative disease other than a successful ly treated 
non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized 
carcinoma in situ of the cervix.  
5. Have  had any prior  treatment  with minocycline.  
6. Presence of visual disturbances and/or headaches suggestive of pseudotumor cerebri at  
screening or baseline (Day 0).  
7. Have a clinical chemistry or hematology laboratory value that is abnormal at the 
screening visit and that is considered clinically significant by [CONTACT_093].  
8. Has an ALT or AST at screening greater than or equal to [ADDRESS_1078803] used on the face an over -the-counter (OTC) topi[INVESTIGATOR_784331], topi[INVESTIGATOR_900] -inflammatory medications, 
corticosteroids, salicylic acid, α -hydroxy/glycolic, ant ibacterial/antiseptic soap or wash 
within 14 days prior to baseline (Day 0). Topi[INVESTIGATOR_784332] (e.g., benzoyl peroxide, salicylic acid) are 
allowed for treatment of acne on the back, shou lders and chest only.  
10. Have used prescription topi[INVESTIGATOR_1832] (e.g. tretinoin, tazarotene, adapalene) or 
antimicrobials (e.g. clindamycin, erythromycin) or other prescription topi[INVESTIGATOR_784333] 28 days of baseline  (Day 0). Topi[INVESTIGATOR_8163] 
(not containing minocycline or other tetracycline -class antibiotics) may be used to treat 
non-acne skin lesions outside the face.  
11. Have used systemic antibiotics or other systemic anti -acne drugs not mentioned in the 
exclusion criteria within 28 days of baseline (Day 0).  
12. Have used oral, intranasal, or injectable corticosteroids within 28 days of baseline (Day  
0) or require them during the study. Inhaled corticosteroids for stable medical conditions 
are allowed.  
13. Have received an investigational therapy (including investigational drug or procedure) 
within 28 days of baseline (Day 0) or plan to use one during the study.  
14. Have had a facial procedure (e.g. chemical peel, laser, microdermabrasion) within 8 
weeks of baseline (Day 0).  
15. Have excessive sun exposure, is planning a trip to a sunny climate or used tanning booths 
within  28 days prior  to baseline  (Day  0) or is not willing  to minimize  natural  and artificial 
sunlight exposure during the study. Use of sunscreen products and protec tive apparel are 
recommended when exposure cannot be avoided.  
BioPharmX – Protocol BPX -01-C04- BPX-[ADDRESS_1078804]  received  photodynamic  therapy  or phototherapy  with blue or red light within  12 
weeks of baseline (Day 0).  
17. Have  used androgen  receptor  blockers  (such  as spi[INVESTIGATOR_784334])  within  12 
weeks of baseline (Day 0).  
18. Have  used drospi[INVESTIGATOR_187306],  chlormadinone  acetate,  and cyproterone  acetate  within  26 weeks 
of baseline (Day 0).  
19. Have used oral retinoid (e.g., isotretinoin) within 52 weeks prior to baseline (Da y 0) or  
vitamin A supplements greater than 10,000 U/d within 26 weeks of baseline (Day 0).  
20. History  of clinically  significant  drug or alcohol  abuse  in the last year prior  to baseline  
(Day 0) as judged by [CONTACT_093].  
21. Has known  or suspected  allergy  to minocycline,  tetracycline -class  antibiotics  or any 
component of the investigational product.  
 
Statistical  Analysis:  
 
No statistical analysis will be performed for this small study. T he low sample size will provide 
directional data only and no statistical significance between or within treatment groups is 
expected.  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 15 of 47   
BioPharmX – Protocol BPX -01-C04- BPX-[ADDRESS_1078805] prevalent skin disorder and it affects approximately 85% of the 
population at some time between the age of 12 and 24 years, and it frequently persists into 
adulthood.1,2 Acne is a multifactorial chronic disease and different facto rs contribute to its 
development such as: (1) sebaceous gland hyperactivity with seborrhea, (2) abnormal 
keratinocyte desquamation, and (3)  bacterial colonization and proliferation responsible for local 
inflammatory changes.3,[ADDRESS_1078806], and back: (1) noninflammatory open and closed comedones 
and (2) inflammatory papules, pustules and nodules. During puberty, surges in androgen  cause 
over production of sebum  along with abnormal desquamation of the epi[INVESTIGATOR_784335]. Formed by [CONTACT_784358], the comedones provide an ideal environment for the 
proliferation of Propi[INVESTIGATOR_784336]. A wide variety of drug products, 
topi[INVESTIGATOR_166470], are available to treat acne. The most effective acne therapi[INVESTIGATOR_784337].  
 
Because of their known anti -inflammatory properties, minocycline products have been 
particularly successful in the treatment of moderate to severe inflammatory acne vulgaris. 
However, there have been severe side effects associated with the oral dosage forms o f 
minocycline. There is currently no commercially available topi[INVESTIGATOR_784338].  
 
1.2 BPX -01 Minocycline  in Acne  Vulgaris  
BPX -01 is a topi[INVESTIGATOR_784339] (HCl) as the drug substance. It is 
a hydrophilic formulation that relies on full dissolution of the drug substance to ensure efficient 
and targeted delivery to the facial skin. In preclinical stu dies, uptake of BPX -01 has been 
confirmed to reach the epi[INVESTIGATOR_784340], with local levels above the minimum 
inhibitory concentration (MIC) value for P. acnes .[ADDRESS_1078807]  a number  of gram-positive  and gram -negative  organisms, 
including P. acnes . The mechanism through which minocycline ameliorates acne is not fully 
elucidated, although reducing the bacterial count may reduce the size and quantity of lesions by 
[CONTACT_389077].6,7,8 
 
BPX -01, 1% gel is intended for use in the treatment of non -nodular, moderate to severe 
inflammatory acne vulgaris in patients 9 years of age and older. There has been one clinical  
study (Phase 2a) completed with BPX -01 1% minocycline topi[INVESTIGATOR_784341] (Phase 2b) completed with BPX -01 1% and 2% minocycline topi[INVESTIGATOR_34600].  
BioPharmX – Protocol BPX -01-C04- BPX-[ADDRESS_1078808] of 1 and 2% topi[INVESTIGATOR_784342] -nodular acne vulgaris.  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 18 of 47  2 STUDY  HYPOTHESIS  AND  OBJECTIVE(S)  
2.1 Hypothesis  
BPX -01 improves  disease  condition  in subjects  with moderate  to severe  inflammatory  non-
nodular acne vulgaris . 
 
2.2 Objectives  
Primary:  
• To obtain photo -documentation of the efficacy of BPX -01 minocycline 1% or 2% topi[INVESTIGATOR_784343] -nodular acne vulgaris  
Secondary:  
• To evaluate  the cutaneous  tolerance  of BPX -01 minocycline  1% or 2% topi[INVESTIGATOR_784344] – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 19 of 47  3 STUDY  ENDPOINTS  
3.1 Primary  Endpoint  
• Change  from  baseline  in inflammatory  lesion  counts  at Week  12 
 
3.2 Secondary  and Exploratory  Endpoints  
Secondary  Efficacy  Endpoint:  
• Change  from  baseline  in inflammatory  lesion  counts  at Weeks  1, 2, 4, and 8 
Exploratory  Efficacy  Endpoints:  
• Subjects  with at least a two-grade  reduction  in IGA at Week  12 
• Percent  change  from  baseline  in inflammatory  lesion  counts  at Weeks  1, 2, 4, 8, and 12 
• Absolute  change  and percent  change  from  baseline  in noninflammatory  lesion  counts  at 
Weeks 1, 2, 4, 8, and 12  
• Absolute change and percent change from baseline in total lesion counts at Weeks 1, 2, 4,  
8, and 12  
• Absolute change and percent change from baseline in the Investigator’s Global Assessment 
(IGA) at Weeks 1, 2, 4, 8, and 12  
• Proportion of subjects with an IGA of clear (0) or almost clear (1) at Weeks 1, 2, 4, 8, and 
12 
• Proportion  of subjects  with at least a two-grade  reduction  in IGA at Weeks  1, 2, 4, and 8 
• Change from baseline in Patient Global Impression of Severity (PGI -S) at Weeks 1, 2, 4, 8, 
and 12  
• Patient  Global  Impression  of Improvement  (PGI -I) at Weeks  1, 2, 4, 8, and 12 
Safety  Endpoints:  
• Incidence  of treatment -emergent  adverse  events  (TEAEs)  
• Shift  from  baseline  in clinical  hematology  and chemistry  laboratory  tests 
• Change  from  baseline  in the cutaneous  tolerance  score  evaluated  by [CONTACT_63634] 
(erythema, scaling -peeling, edema)  
• Change from baseline in the cutaneous tolerance score evaluated by [CONTACT_423] (tightness, 
burning, stinging, itching)  
• Incidence  of visual  disturbances/headaches  suggestive  of pseudotumor  cerebri  and 
minocycline -induced skin hyperpi[INVESTIGATOR_371]  
• Incidence  of product  related  facial  staining  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 20 of 47  4 STUDY  DESIGN  
This is a 12-week,  multi -center,  open  label,  two-arm study.  
 
Subjects will be assigned to treatment with 1% or 2 % BPX -[ADDRESS_1078809] 30 minutes before bedtime each night for 12  weeks. 
Lesion counts, IGA, and Patient -Reported Outcomes (PGI -S and P GI-I) will be performed to 
assess efficacy. Photographs will be taken to document treatment effect.  
 
Safety will be assessed with the vital signs, brief physical examination, clinical laboratory tests, 
cutaneous tolerance score, incidence of minocycline -induced skin hyperpi[INVESTIGATOR_371], incidence 
of visual disturbances and/or headaches suggestive of pseudotumor cerebri, incidence of product 
related facial staining and collection of adverse events.  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 21 of 47  5 STUDY  POPULATION  
This study  will include  up to 40 subjects  with moderate  to severe  inflammatory  non-nodular  acne 
vulgaris, defined as IGA score of 3 (moderate) or 4 (severe), [ADDRESS_1078810] 
dose of study drug will not be replaced.  
 
5.1 Inclusion  Criteria  
Subjects will be eligible if they meet all of the following criteria at the screening and baseline 
(Day  0) visits, unless specified otherwise:  
 
1. Male or female subjects aged between [ADDRESS_1078811] at unacceptable risk or could interfere with study 
assessments or integrity of the data.  
3. Moderate  to severe  inflammatory  non-nodular  acne vulgaris,  defined  as follows:  
a. IGA score  of 3 (moderate)  or 4 (severe)  at baseline  (Day  0); 
b. 20-60 inflammatory  lesions  on the face at baseline  (Day  0); 
c. 0-100 noninflammatory  lesions  on the face at baseline  (Day  0); 
d. Maximum  of 2 nodules  (≥ 5 mm)  on the face at baseline  (Day 0). 
4. Female subjects of childbearing potential (including pre -puberty) are willing to use  
effective contraceptive method for at least 28 days before baseline (Day 0) and at least  
[ADDRESS_1078812]  a sterilized  or same -sex partner 
for the duration of the study. Effective contraceptive methods are: syste mic hormonal 
contraceptives, intrauterine device or barrier method of contraception in conjunction with 
spermicide, or agree to sexual abstinence. Hormonal contraceptives must be on a stable 
dose for at least 12 weeks before baseline (Day 0). Subjects usin g low dose oral 
contraceptives must use a second form of birth control (e.g., barrier method such as 
condoms with spermicide).  
Note:  Female  subjects  of nonchildbearing  potential  are defined  as follows:  
a. Female subjects who have had surgical sterilization (hysterectomy, bilateral 
oophorectomy, bilateral salpi[INVESTIGATOR_1656], or bilateral tubal ligation);  
b. Female subjects who have had a cessation of menses for at least 12 months and a 
follicle -stimulating hormone ( FSH) test confirming nonchildbearing potential 
(refer to the central laboratory reference range for menopausal women) or 
cessation of menses for at least 24 months without FSH levels confirmed;  
5. Female subjects of childbearing potential must have a negative  urine pregnancy test at 
screening and baseline (Day 0).  
6. Treatment  with hormonal  therapy  must  be on a stable  dose and frequency  for at least 
12 weeks before baseline (Day 0) and must remain stable throughout the study.  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 22 of 47  7. Subjects who use make -up, facial moisturizers, creams, lotions, cleansers and/or 
sunscreens must have used the same product brands/types for a minimum period of 14  
days prior to baseline (Day 0), must agree not to change brand/type or frequency of use 
throughout the study and must agree not to use make -up, facial moisturizers, creams, 
lotions, cleansers and/or sunscreens on the clinic visit days before the visit.  
8. Subjects must be capable of giving informed consent and the written informed consent 
must be obtained prior to any study -related procedures. Subject under [ADDRESS_1078813] sign an assent form, and their parent(s) or legal representative must have read an d 
signed the informed consent form prior to any study -related procedures.  
 
5.2 Exclusion  Criteria  
Subjects will not be eligible if they meet any of the following criteria at the screening or baseline 
(Day 0) unless specified otherwise:  
 
1. Female subject who is breastfeeding, pregnant or who is planning a pregnancy during the 
study.  
2. Have  acne fulminans  or conglobata,  or nodulocystic  acne.  
3. Have a history of skin disease, presence of skin condition, skin pi[INVESTIGATOR_784330], in the opi[INVESTIGATOR_871], would interfere with the study.  
4. Have a history of cancer or lymphoproliferat ive disease other than a successfully treated 
non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized 
carcinoma in situ of the cervix.  
5. Have  had any prior  treatment  with minocycline.  
6. Presence of visual disturbances and/or headaches s uggestive of pseudotumor cerebri at 
screening or baseline (Day 0).  
7. Have a clinical chemistry or hematology laboratory value that is abnormal at the 
screening visit and that is considered clinically significant by [CONTACT_093].  
8. Has an ALT or AST at scre ening greater than or equal to [ADDRESS_1078814] used on the face an over -the-counter (OTC) topi[INVESTIGATOR_784331], topi[INVESTIGATOR_900] -inflammatory medications, 
corticosteroids, sali cylic acid, α -hydroxy/glycolic, antibacterial/antiseptic soap or wash 
within 14 days prior to baseline (Day 0). Topi[INVESTIGATOR_784332] (e.g., benzoyl peroxide, salicylic acid) are 
allowed for treatment of acne on the back, shoulders and chest only.  
10. Have used prescription topi[INVESTIGATOR_1832] (e.g. tretinoin, tazarotene, adapalene) or 
antimicrobials (e.g. clindamycin, erythromycin) or other prescription topi[INVESTIGATOR_784333] 28 days of baseline (Day 0). Topi[INVESTIGATOR_8163] 
(not containing minocycline or other tetracycline -class antibiotics) may be used to treat 
non-acne skin lesions outside the face.  
11. Have used systemic antibiotics or other systemic anti -acne drugs not mentioned in the 
exclusion criteria within 28 days of baseline (Day 0).  
BioPharmX – Protocol BPX -01-C04- BPX-[ADDRESS_1078815] used oral, intranasal, or injectable corticosteroids within 28 days of baseline (Day  
0) or require them during the study. Inhaled corticosteroids for stable medical conditions 
are allowed.  
13. Have received an investigational therapy (including investigational drug or procedure) 
within 28 days of baseline (Day 0) or plan to use one during the study.  
14. Have had a facial procedure (e.g. chemical peel, laser, microdermabrasion) within 8 
weeks of baseline (Day 0).  
15. Have excessive sun exposure, is planning a trip to a sunny climate or used tanning booths 
within  28 days prior  to baseline  (Day  0) or is not willing  to minimize  natural  and artificial 
sunlight exposure during the study. Use of sunscreen products and protective apparel are 
recommended when exposure cannot be avoided.  
16. Have received photodynamic therapy or phototherapy with blue or red light wi thin 12 
weeks of baseline (Day 0).  
17. Have used androgen receptor blockers (such as spi[INVESTIGATOR_294698]) within 12 
weeks of baseline (Day 0).  
18. Have  used drospi[INVESTIGATOR_187306],  chlormadinone  acetate,  and cyproterone  acetate  within  26 weeks 
of baseline (Day 0).  
19. Have used oral retinoid (e.g., isotretinoin) within 52 weeks prior to baseline (Day 0) or 
vitamin A supplements greater than 10,000 U/d within 26 weeks of baseline (Day 0).  
20. History of clinically significant drug or alcohol abuse in the last year prior to ba seline 
(Day 0) as judged by [CONTACT_093].  
21. Has known or suspected allergy to minocycline, tetracycline -class antibiotics or any 
component of the investigational product.  
 
5.[ADDRESS_1078816] the right to withdraw from the study at any time for any reason without penalty. 
The investigator also has the right to withdraw subjects from the study if he/she feels it is in the 
best interest of the subject or if the subject is uncooperat ive or noncompliant. Should a subject 
decide to withdraw, all efforts will be made to complete and report the observations as 
thoroughly as possible, particularly the follow -up examination.  
 
The investigator  or one of his  or her staff members  should  contact  [CONTACT_784359] a personal visit to determine as completely as possible the reason for the withdrawal. 
A complete final evaluation at the time the subject’s withdrawal should be made with an 
explanation of why the subject  is withdrawing from the study. If the reason for removal of a 
subject is an adverse event or an abnormal laboratory test result, the principal specific event or 
test will be recorded. The criteria for enrollment must be followed explicitly. Subjects who 
discontinue  the study  after taking  his or her first dose,  but before  the Week  [ADDRESS_1078817] assessments listed at Week 12 (exit visit). Subjects who 
discontinue will not be replaced.  
 
Reasons  for discontinuation  include  the following:  
• The investigator  decides  that the subject  should  be withdrawn.  If this decision  is made  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 24 of 47  because of a serious adverse event, the study drug is to be discontinued and appropriate 
measures are to be taken. The investigator will notify the sponsor immediately.  
• The attending  physician  requests  that the subject  be withdrawn  from  the study.  
• The subj ect for any reason requires treatment with another therapeutic agent that has been 
demonstrated to be effective for treatment of the study indication. In this case, 
discontinuation from the study occurs immediately upon introduction of the new agent.  
• The s ubject is lost to follow -up. In this case, a reasonable attempt to contact [CONTACT_784360], and these attempts must be documented.  
• The sponsor or regulatory authorities, for any reason, stop the study. All subjects will be 
discontinued from the study and notified of the reasons for the discontinuation.  
• Pregnancy  occurs  at any time during  the study.  
• Presence  of clinically  significant  symptoms  suggestive  of pseudotumor  cerebri.  
• Other: the subject may withdraw from the study for any other reason, including withdrawal  
of consent.  
BioPharmX – Protocol BPX -01-C04- BPX-[ADDRESS_1078818] should read and sign an informed consent form prior to any 
screening procedures being performed. This study involves a compa rison of 1% and 2% BPX -[ADDRESS_1078819] 30 minutes before bedtime each night for a total 
duration of 12  weeks. Subjects will be assigned sequentially to either 1 or 2% BPX -01 in a 1:1 
ratio on Day 0 (baseline) as follows:  
 
1st 10 subjects: BPX -01 1%, 1 g topi[INVESTIGATOR_784345] a day for 12 weeks 
2nd 10 subjects:  BPX -01 2%, 1 g topi[INVESTIGATOR_784346]  a day for 12 weeks  
Subjects  should  complete  their cleansing  routine  (e.g.,  washing  face,  bathe,  shower,  shaving)  and 
have a clean face pri or to study drug application and should not apply anything else to their face 
afterward in the evening. Every effort should be made to keep the same skin care habits 
throughout the study.  
 
If an application is missed, subjects should apply the study product as soon as they remember on 
the same  day. However,  if it is the next day, the missed  dose should  be skipped  and the next dose 
taken as normal. No double dose should be taken for any reason.  
 
6.2 Study  Treatment  
 
6.2.1 Description  
 
BPX -01 (1% and 2%) is formulated as a topi[INVESTIGATOR_784347]. The gel will be provided by [CONTACT_784361] -dose, alumin um tubes lined with an 
inert, biocompatible material.  Each tube will contain 1.[ADDRESS_1078820] (used and unused tubes) will be 
returned to the sponsor or designee after the study completion.  
 
6.2.[ADDRESS_1078821] at 15°C to 30°C with protection from moisture. It will only 
be supplied  to subjects  in the trial under  the supervision  of the investigator.  Room  temperature  on 
site will be monitored  and recorded.  The packaging  of investigational  product  for this clinical  
BioPharmX – Protocol BPX -01-C04- BPX-[ADDRESS_1078822] dose that will be 
applied on site at the baseline (Day 0) visit under the supervision of the study staff.  
 
The study drug will be dispensed in a medication kit by [CONTACT_1758] s ite to the subjects and will be 
given with subject instructions for application. At baseline (Day 0) and Week 2 visits, subjects 
will receive one medication kit containing 18 tubes each. At Week 4 and Week 8 visits, subjects 
will receive two kits for a tot al of 36 tubes each. Single -use tubes of 1.5 g (for delivery of 1 g of 
gel) will be given and 1 g of gel is to be applied on the entire face once daily. Subjects are to 
return all tubes (used and unused) to the study site at the Week 1, 2, 4, 8, and [ADDRESS_1078823] does not return study drug, he or she will 
be instructed to return it as soon as possible.  
 
6.2.4 Drug  Accountability  
 
The investigator is responsible for maintaining accurate records of the study drug received 
initially, the study drug dispensed/used/returned by [CONTACT_784362]. All study drug accountability forms and treatment logs must 
be retained in the Investigator’s study file. These reco rds must be available for inspection at any 
time by [CONTACT_456], its designees or by [CONTACT_17513].  
 
6.2.5 Method  of Assignment  to Treatment  
 
Up to 40 subjects  will be  assigned  sequentially  (1:1)  to one of the two treatment  groups.  
 
6.2.6 Rationale  for Selection  and Timing  of Doses  in the Study  
 
In preclinical studies, different BPX -01 formulations (1% and 4%) were applied as mg/cm2 to 
cover approximately 5% to 15% of body surface area (BSA). Topi[INVESTIGATOR_784348] -01 
once daily demonstrated rapid absorption in rats at all doses. The amount of BPX -01 1% 
minocycline detected in rats at the 2.5 mg/cm2/d dose group represents the ma ximum amount of 
absorption, because rat skin is thinner than human skin. No systemic uptake of minocycline was 
seen in the low dose group in minipi[INVESTIGATOR_14107]. The lack of minocycline in plasma with delivery of  
BPX -01 1% minocycline in minipi[INVESTIGATOR_22736] 2.5 mg/cm2/d is v ery promising because it supports the 
hypothesis that targeted delivery of minocycline to the skin with limited systemic exposure is 
possible.5 
 
The uptake  of minocycline  in minipig  skin shows  levels  above  the MIC  value  for P. acnes , 
which  was found  to be 0.035  µg/mL.  Therefore,  on the basis  of these  results,  BPX -01 1% 
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 27 of 47  minocycline at 2.5  mg/cm2/day is the proposed first -in-human clinical dose (1 g of BPX -01, 1%  
minocycline applied as a thin film to the entire face) that was used in a Phase 2a study.5 In a 
currently ongoing 2b dose finding study, the 1% and 2% doses are being evaluated to establish 
the lowest effective dose. This current open label study will pro vide early data on the correlation 
between IGA, lesion counts and photo -documentation.  
 
6.2.7 Assessment  of Treatment  Compliance  
 
Compliance to treatment with BPX -01 minocycline 1% or 2% will be monitored at each visit. 
Compliance to treatment will be assessed b y direct questioning, review of the subject’s diary,  
and by [CONTACT_141909]. The tubes containing study  
drug will be collected from each subject at the Week 1, 2, 4, 8, and [ADDRESS_1078824] will be considered significantly noncompliant if he or she 
intentionally  or repeatedly  takes  more  than the prescribed  amount  of medication  in the same  time 
frame as judged by [CONTACT_093].  
 
6.3 Concomitant  Therapy  
All medications (including OTC drugs, vitamins, and antacids) taken less than or equal to [ADDRESS_1078825] be recorded.  
 
The investigator should assess for acceptability any concomitant procedures, medications, and 
dietary supplements that are not explicitly prohibited.  
 
Medication entries may be captured a s generic or trade names. Trade names should be used for 
combination drugs. Entries should include as much as possible of the following information: the 
dose, unit, frequency of administration, route of administration, start date, discontinuation date, 
and indication. If the medication is discontinued or the dosage changed, these details must be 
recorded.  
 
6.3.1 Permitted  Therapi[INVESTIGATOR_784349]:  
• Topi[INVESTIGATOR_784350] (e.g. 
benzoyl  peroxide,  salicylic  acid)  are allowed  for treatment  of acne on the back,  shoulders  and 
chest only;  
• Topi[INVESTIGATOR_390099]  (not containing  minocycline  or other  tetracycline -class  antibiotics)  may be 
used to treat non -acne skin lesions outside the face;  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 28 of 47  • Inhaled  corticosteroids  for stable  medical  conditions  are allowed;  
• Hormonal therapi[INVESTIGATOR_014] (including oral contraceptives) are allowed but must be on stable dose 
and frequency for at least 12 weeks before baseline (Day 0) and must remain stable 
throughout the study (see inclusion criteria, Section 5.1, for more details);  
• Subje cts will be instructed that the use of make -up, facial moisturizers, creams, lotions, 
cleansers and/or sunscreens are permitted but they must use the same brands/types for a 
minimum period of 14 days prior to baseline (Day 0) and must agree not to change  
brand/type or frequency of use throughout the study. Subjects must also agree not to use 
make -up, facial moisturizers, creams, lotions, cleansers and/or sunscreens on the clinic visit 
days before the visit;  
• Subjects who choose to use make -up, facial moistur izers, creams, lotions, cleansers and/or 
sunscreens should try to use non -comedogenic products.  
 
6.3.2 Prohibited  Therapi[INVESTIGATOR_784351]:  
• The use of any OTC topi[INVESTIGATOR_784352], topi[INVESTIGATOR_900] -inflammatory medications, corticosteroids, salicylic 
acid, α -hydroxy/glycolic, antibacterial/antiseptic soap or wash within 14 days prior to 
baseline (Day 0) and throughout the study;  
• The use of any prescription topi[INVESTIGATOR_1832] (e.g. tretinoin, tazarotene, adapalene) or 
antimicrobials (e.g. clindamycin, erythromycin) or any other prescription topi[INVESTIGATOR_784333] 28 days of baseline (Day 0) and throughout the  
study (except  topi[INVESTIGATOR_784353] -acne skin lesions as indicated in Section 6.3.1 ); 
• The use of systemic antibiotics or other systemic anti -acne drugs not mentioned in the  
exclusion criteria (Section 5.2) within 28 days of baseline (Day 0)  and throughout the study;  
• The use of oral, intranasal, or injectable corticosteroids within 28 days of baseline (Day 0) 
and throughout the study;  
• The use of androgen receptor blockers (e.g., spi[INVESTIGATOR_8407], flutamide) within 12 weeks of 
baseline (Day 0) and throughout the study;  
• The use of an oral retinoid (e.g., isotretinoin) within 52 weeks prior to baseline (Day 0) or 
vitamin A supplements greater than 10,000 U/d within 26 weeks of baseline (Day  0) and 
throughout the study;  
• Facial procedures (e.g. chemical peel, laser, microderma brasion) within 8 weeks of baseline 
(Day 0) and throughout the study;  
• Photodynamic therapy or phototherapy with blue or red light within 12 weeks of baseline 
(Day 0) and throughout the study;  
• The use of drospi[INVESTIGATOR_187306], chlormadinone acetate, and cyproterone acetate within 26 weeks of 
baseline (Day 0) and throughout the study;  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 29 of 47  • The use of another investigational therapy within 28 days of baseline (Day 0) and throughout 
the study.  
BioPharmX – Protocol BPX -01-C04- BPX-[ADDRESS_1078826] has agreed to participate and has 
signed and dated the informed consent form. No treatment or trial -related procedures will be 
initiated before the informed consent is signed. The baseline (Day 0) visit must be performed, at 
the latest, 30 days after the screening visit.  
 
Screening evaluation will be performed according to inclusion and exclusion criteria. If the  
individual fulfills all inclusion criteria and no exclusion criteria, he or she may be included in the 
study.  
 
Table  1 provides  a description  of the procedures  to be performed  at each visit.  
 
Table  1 : Schedule  of Events  
 
 
Procedures/  Time 
Points:   
Visit  1  
Visit  2  
Visit  3  
Visit  4  
Visit  5  
Visit  6  
Visit  7  
Visit  8 
 
Screening  Baseline  / 
Day 0   
Week 1  
Week 2  
Week 4  
Week 8  
Week  12 TBD5 
Recurrence  
Visit  windows  –30 to –1 d  ±3 d ±3 d ±3 d ± 3 d ±3 d n/a 
Informed consent, 
medical  history  and 
HIPAA   
X        
Demographics  X        
Collect/Record  
Concomitant 
Medications   
X  
X  
X  
X  
X  
X  
X  
X 
Eligibility  Assessment  X X       
Brief  Physical  
examination  X      X  
Vital  signs1 X      X  
Basic  Chemistry  and 
Hematology 
Laboratory  Panel2  
X       
X  
Urine  Pregnancy  Test3 X X     X  
Patient  global  
impression  of severity 
(PGI -S)   
X  
X  
X  
X  
X  
X  
X 
Patient  global 
impression  of 
improvement  (PGI -I)    
X  
X  
X  
X  
X  
X 
Investigator  Global  
Assessment  (IGA)  X X X X X X X X 
Lesion  Counts  X X X X X X X X 
Investigator  Cutaneous  
Tolerance  Scores4  X X X X X X  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 31 of 47   
Procedures/  Time 
Points:   
Visit  1  
Visit  2  
Visit  3  
Visit  4  
Visit  5  
Visit  6  
Visit  7  
Visit  8 
 
Screening  Baseline  / 
Day 0   
Week 1  
Week 2  
Week 4  
Week 8  
Week  12 TBD5 
Recurrence  
Visit  windows  –30 to –1 d  ±3 d ±3 d ±3 d ± 3 d ±3 d n/a 
Subject  Cutaneous  
Tolerance  Scores4  X X X X X X  
Presence  or absence  of 
visual 
disturbances/headache 
s suggestive of  
pseudotumor  cerebri     
 
X  
 
X  
 
X  
 
X  
 
X  
Presence  or absence  of 
minocycline -induced 
skin 
hyperpi[INVESTIGATOR_371]     
X  
X  
X  
X  
X  
X 
Presence  or absence  of 
minocycline -induced 
skin staining     
X  
X  
X  
X  
X  
X 
Photography   X X X X X X X 
Test Product 
Dispensed  to Subject  
along with subject’s  
instructions    
X  
X  
X  
X  
X   
Subject  Dairy  
Distribution/Collectio 
n/Review    
X  
X  
X  
X  
X  
X  
Collect  All Study  
Medication  Supplies  / 
Drug Accountability     
X  
X  
X  
X  
X  
Collect  and Record  
Adverse  Events   X X X X X X  
Subject  Satisfaction  
Questionnaire        X  
FSH = follicle -stimulating hormone; HIPAA = Health Insurance Portability and Accountability Act of 
1996.  
1Include height and weight. Height will be  measured only at screening.  
2Include FSH levels (at screening only) for female subjects who have had a cessation of menses for at 
least 12 months but less than 24 months.  
3Female  subjects of  childbearing potential only  (including pre -puberty).  
4Cutaneous  Tolerance  Score  
- Observer  reported:  erythema,  scaling -peeling,  edema.  
- Self-Reported:  tightness,  burning,  stinging,  itching.  
5Subjects should be instructed to call the office to schedule a visit as soon as acne recurrence is noted. 
Subjects should also be instructed to avoi d any acne treatments until the final in office evaluation has 
been made.  
BioPharmX – Protocol BPX -01-C04- BPX-[ADDRESS_1078827] (board certified or equivalent) or designee. To ensure consistency and reduce 
variability, the same assessor should perform all assessments on a given sub ject whenever 
possible.  
 
The following  points  must  be noted  regarding  to the order  of the efficacy  assessments:  
 
• PROs  (Patient  Global  Impression  Questionnaires)  should  be completed  prior  to any other  
assessments to avoid bias in the subject’s evaluation.  
• The assessment  of the IGA should be  performed  before  the lesion counts.  
• Acne  lesion  counts  are to  be performed  after the  PROs  and IGA evaluations.  
• Baseline  assessments  should  be performed  prior  to first product  administration.  
The time when  each assessment  is performed  will be documented  in the source  document  and/or 
eCRF.  
 
8.1.1 Acne  Lesion  Counts  
 
The number of acne lesions on the face (papules, pustules, nodules, and open and closed 
comedones) will be counted at every visit, according to the following definitions. The nose is 
excluded for the comedone counts.  
 
Inflammatory  lesions:  
Papule : A small,  solid elevation  5 mm or  less in diameter.  
 
Pustule : A small,  circumscribed  elevation  of the skin that contains  yellow -white 
exudate.  
 
Nodule :  A circumscribed,  elevated,  lesion  generally  more  than 5 mm in diameter.  
 
Noninflammatory  lesions:  
Open comedone : A mass  of sebaceous  material  that is impacted  behind  an open 
follicular orifice (blackhead)  
 
Closed  comedone : A mass  of sebaceous  material  that is impacted  behind  a closed 
follicular orifice (whitehead)  
 
Subjects will be examined in a well -lit room and without the aid of magnifying instruments.  
Total number of lesions and number of each type of lesion (papule, pustule, nodule, closed and 
open comedone) should be reported.  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 33 of 47  8.1.2 Investigator  Global  Assessment  (IGA)  
 
The Investigator’s Global Assessment (IGA) of Disease Severity will be assessed at every study 
visit. The IGA is a global assessment of the current state of the disease. It is a 5 -point 
morphological assessment of overall disease severity; assessment will be determined according  
to the following categories: 0  (clear), 1 (almost clear), 2 (mild severity), 3 (moderate severity) 
and 4 (severe).  To be eligible, subjects must have an IGA score of 3 or 4 at the baseline (Day 0) 
visit. The IGA is an overall global  evaluation of acne that should be performed at arm’s length 
distance from the patient. A detailed description of IGA scores is provided in Table 2 . 
 
Table  2 : Investigator’s  Global  Assessment  Scale  for Acne  Vulgaris  
 
Grade  Description  
[ADDRESS_1078828]  clear; rare noninflammatory  lesions  with no more than one small  inflammatory  lesion  
2 Mild severity;  greater  than Grade  1; some noninflammatory  lesions  with no more than a few 
inflammatory  lesions  (papules/pustules  only, no nodular  lesions)  
3 Moderate  severity;  greater  than Grade  2; up to many noninflammatory  lesions  and may have 
some inflammatory  lesions,  but no more than one small nodular  lesion  
4 Severe;  greater  than Grade  3; up to many noninflammatory  and inflammatory  lesions,  but no 
more than a few nodular  lesions  
Source:  FDA Draft guidance  on Acne Vulgaris 9 
 
8.1.3 Patient -Reported  Outcomes  (PROs)  
 
[IP_ADDRESS]  Patient  Global  Impression  of Severity  (PGI -S) 
 
The patient  global  impression  of severity  is a single -item question  that asks the subject  to rate the 
current  severity  of his or her acne.  It will be assessed  at baseline  (Day  0), and at the Week  1, 2, 4, 
8, and 12 visits.  
 
Overall,  how would  you rate the severity  of your acne  now?  
 
The responses  are as follows10: 
 
1. Clear  skin 
2. Mild 
3. Moderate  
4. Severe  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 34 of 47  [IP_ADDRESS]  Patient  Global  Impression  of Improvement  (PGI -I) 
 
The patient global impression of improvement is a single -item question that asks the subject to 
rate the current symptom severity compared with how it was before taking the study medication 
(“Very much better” to “Very much worse”). It will be assessed at the Week 1, 2, 4, 8 and 12 
visits.  
 
Overall, how would you rate the change in severity of your acne compared with how it was 
before you started taking the medication in this study?  
 
The responses  are as follows10: 
 
1. Very  much better  
2. Much  better  
3. A little better  
4. No change  
5. A little  worse  
6. Much  worse  
7. Very  much worse  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 35 of 47  8.1.4 Photographic  Documentation  
 
Photographic  documentation  of changes  from  baseline  in the disease  condition  will be performed  
at baseline, weeks 1, 2, 4, 8, 12 and at the follow -up visit. Every effort will be made to 
standardize lighting, facial orientation, and distance from the camera to minimize between 
assessment variability due to image capture.  
 
8.2 Safety  Assessments  
 
8.2.1 Vital Signs 
 
The following vital signs will be recorded at screening and Week 12 visits (exit visit) in a seated 
position, after having sat calmly for at least 5 minutes: systolic and diastolic blood pressure 
(mmHg), pulse (bpm) and body temperature (°C).  
 
Weight (kg) and height (cm) will be recorded at the screening visit . The weight will also be 
recorded at the Week 12 visit (exit visit).  
 
Any abnormal finding related to vital signs that the investigator considers to be clinically 
significant, must be reco rded as an AE.  
 
8.2.2 Brief  Physical  Examination  
 
The following sites/systems will be included in the brief physical examination that will be 
performed at screening and Week 12 visits (exit visit). Each system will be scored as 
normal/abnormal (non -clinically si gnificant or clinically significant). Pertinent details must be 
recorded for any clinically significant findings.  
 
• General  appearance  
• Dermatological  (except  acne on the face)  
• Respi[INVESTIGATOR_696]  
• Cardiovascular  
• Abdominal  
 
8.2.[ADDRESS_1078829] chemistry panel (chemistry includes liver function 
tests).  In addition,  at the screening,  baseline  (Day  0), a urine  pregnancy  test will be performed  for 
female subjects of childbearing potential (including pre -puberty) at the investigator site. The 
specific tests in these panels are listed in Table 3.  
BioPharmX – Protocol BPX -01-C04- BPX-[ADDRESS_1078830], Chloride, CK, Creatinine 
(Enzymatic),  GGT,  Glucose  Random,  LDH,  Potassium,  Sodium,  Total 
Bilirubin, Urea (BUN), Uric Acid  
Urine  pregnancy  test For females of childbearing potential (screening, baseline (Day 0) a nd 
Week 12 visits (exit visit))  
Laboratory tests 
required at screening 
only FSH levels  for female  subjects  who have  had a cessation  of menses  for 
at least 12 months but less than 24 months.  
ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; CK =  
creatine  kinase;  FSH = follicle -stimulating  hormone;  GGT  = gamma -glutamyl  transferase;  HCT  = 
hematocrit;  HGB  = hemoglobin;  LDH  = lactate  dehydrogenase;  MCH  = mean  corpuscular  hemoglobin; 
MCV  = mean  corpuscular  volume;  RBC  = red blood  cell (count);  WBC  = white  blood  cell (count).  
 
Details about the collection and storage of clinical laboratory samples will be provided in the 
laboratory manual.  
 
8.2.4 Cutaneous  Tolerance  Scores  
 
Grading of local site reactions/tolerance will be performed at baseline (Day 0), and at Weeks 1,  
2, 4, 8, and 12 and at the follow -up visit. At the baseline (Day 0) visit, the tolerance assessments 
are to be performed before the drug application.  
 
The inve stigator (or qualified evaluator) will assess the presence and degree of erythema,  
scaling -peeling and edema at the application site using a 4 -point scale, where 0=None, 1= Mild, 
2= Moderate, and 3=Severe.  
 
Erythema:  
0 – None  No evidence  of erythema  present  
1 – Mild  Slight  pi[INVESTIGATOR_22766]  
2 – Moderate  Definite  redness  
3 – Severe  Marked  erythema,  bright  red to dusky  dark red in color  
 
Scaling -peeling:  
0 – None  No scaling  
1 – Mild  Barely  perceptible,  fine scales  present  to limited  areas  of the face 
2 – Moderate  Fine sca le generalized to all areas of the face  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 37 of 47  3 – Severe  Scaling  and peeling  of skin over all areas  of the face 
 
Edema:  
0 – None  No edema  
1 – Mild  Slight  edema,  barely  perceptible  
2 – Moderate  Definite  edema,  raised  approximately  1mm.  
3 – Severe  Severe  edema,  raised  more  than 1mm  and beyond  exposure  area 
 
The subjects will be  asked to grade  their feeling of burning, stinging, tightness, and itching at the 
application site using a 4 -point tolerability scale, where 0=None, 1= Mild, 2= Moderate, and 
3=Severe.  
 
Burning:  
0 – None  No burning  
1 - Mild  Slight  burning  sensation;  not really  bothersome  
2 – Moderate  Definite  warm,  burning  sensation  that is somewhat  bothersome  
3 – Severe  Hot burning  sensation  that causes  definite  discomfort  and may interrupt  
daily activities and/or sleep  
 
Stinging:  
0 – None  No stinging  
1 – Mild  Slight  stinging  sensation,  not really  bothersome  
2 – Moderate  Definite  stinging  sensation  that is somewhat  bothersome  
3 – Severe  Stinging sensation that causes definite discomfort and may interrupt daily 
activities and/or sleep  
 
Tightness:  
0 – None  No tightness  
1 – Mild  Slight  tightness  sensation,  not really  bothersome  
2 – Moderate  Definite  tightness  sensation  that is somewhat  bothersome  
3 – Severe  Tightness sensation that causes definite discomfort and may interrupt daily 
activities and/or sleep  
 
 
Itching:  
0 – None  No itching  
1 – Mild  Slight  itching,  not really  bothersome  
2 – Moderate  Definite  itching  that is somewhat  bothersome  
3 – Severe  Intense  itching  that may interrupt  daily  activities  and/or  sleep  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 38 of 47  8.2.5 Incidence  of Minocycline -Induced  Skin Hyperpi[INVESTIGATOR_371],  Visual 
Disturbances/Headaches Suggestive of Pseudotumor Cerebri  
Incidence of minocycline -induced skin hyperpi[INVESTIGATOR_371] , visual disturbances/headaches 
suggestive of pseudotumor cerebri will be evaluated by [CONTACT_211675] 0, 1, 2, 4, 8 and 
12 visits as follows:  
 
1) Presence  or absence  of minocycline -induced  skin hyperpi[INVESTIGATOR_371].  
2) Presence  or absence  of headaches  suggestive  of pseudotumor  cerebri.  
3) Presence  or absence  of visual  disturbances  suggestive  of pseudotumor  cerebri.  
 
Any occurrences  of these  specific  events  will be reported  as an AE. 
 
If a subject reports headaches and/or visual disturbances suggestive of pseudotumor cerebri, the 
investigator should consider referral to a neurologist and must promptly contact [CONTACT_784363].  
 
8.2.[ADDRESS_1078831] -related skin staining. If staining is present, 
photographic documentation of the stained area will be ob tained. Note that care should be taken 
to differentiate between actual staining (yellowish discoloration that does not wash off) vs. 
superficial accumulation of product (washes off) or hyperpi[INVESTIGATOR_371] (actual 
purplish/blue/black discoloration of tissues) . 
BioPharmX – Protocol BPX -01-C04- BPX-[ADDRESS_1078832]’s 
medical condition(s) in the appropriate section of the source document and CRF. During the 
study,  site personnel  will again  note any change  in the condition(s)  and the occurrence  and nature 
of any ad verse events.  
 
Any events occurring prior to the baseline visit will be recorded on the Medical History CRF. 
Events occurring after application of the 1st dose of study drug or those that increase in severity 
or frequency will be recorded as treatment -emer gent adverse events (TEAEs) on the Adverse 
Event CRF. All AEs will be described in the source documents and in the CRF.  
 
9.[ADDRESS_1078833]’s history, most recent physical examination findings, and 
concomitant medications.  
 
The following  definitions  will be used to determine  causality  of an AE: 
 
- Not related : temporal relationship of the onset of the AE, relative to the experimental 
treatment is not reasonable or another cause can explain the occurrence of the AE.  
-  Possibly related : temporal relationship of the onset of the AE, relative to the 
experimental treatment is possibly reasonable, follows a known response pattern to the 
treatment to suggest a causal relationship  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 40 of 47  - Related : temporal relationship of the onset of t he AE, relative to the experimental 
treatment is reasonable, follows a known response pattern to the treatment, and an 
alternative cause is unlikely.  
 
9.2 Adverse  Events  Severity  
The intensity of an AE is an estimate of the relative severity of the event made by [CONTACT_784364]. The 
following definitions are to be used to rate the severity of an AE:  
 
- Mild : The symptom is barely noticeable to the subject and does not influence  
performan ce of daily activities. Treatment is not ordinarily indicated.  
 
- Moderate : The symptom is sufficiently severe to make the subject uncomfortable, and 
performance of daily activities is influenced. Treatment may be necessary.  
 
- Severe : The symptom causes sever e discomfort, and daily activities are significantly 
impaired or prevented. Treatment may be necessary.  
 
9.[ADDRESS_1078834] administration the 
event will be recorded as a serious adverse event in the source document and eCRF.  
 
A serious adverse event (experience) or reaction is any untoward medical o ccurrence that at any 
dose:  
 
• results  in death,  
 
• is life -threatening,  
 
• requires  in-patient  hospi[INVESTIGATOR_40088],  
 
• results  in persistent  or significant  disability/incapacity,  or 
 
• is a congenital  anomaly/birth  defect.  
 
NOTE: The term “life -threatening” in the definition of “serious” refers to an event in which 
the subject was at risk of death at the time of the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe.  
 
Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
appropriate in other situations, such as important medical events that may not be immediately 
life-threatening  or result  in death  or hospi[INVESTIGATOR_784354] – Protocol BPX -01-C04- BPX-[ADDRESS_1078835]  be reported to  BioPharmX  on 
an SAE form within 24 hours of the knowledge of the occurrence (this re fers to any AE that 
meets one or more of the aforementioned serious criteria).  
 
Reporting  should  be done  by [CONTACT_784365]:  
Safety  Contact  [CONTACT_7171]:  AnnaMarie  Daniels  (Medical  Monitor)  
E-mail: [EMAIL_14990]  
Telephone:  [PHONE_16376]  
The Medical Monitor will evaluate all SAEs as soon  as the reports are received and will assess 
the expectedness of each SAE to the study treatment. For each SAE received, the Medical 
Monitor will make a determination as to whether the criteria for expedited reporting to relevant 
regulatory authorities hav e been met. The sponsor will manage the expedited reporting of 
relevant safety information to concerned regulatory agencies in accordance with local laws and 
regulations.  
 
9.[ADDRESS_1078836] complete a study -specific Pregnancy Form upon 
confirmation of a pregnancy and send i t to BioPharmX within 24 hours of confirmation of the 
pregnancy (contact [CONTACT_561355]). Post -treatment 
follow -up should be done to ensure subject safety. Pregnancy is not itself an AE or SAE; 
however, maternal/fet al complications or abnormalities will be recorded as AEs or SAEs, as 
appropriate. The investigator will follow the pregnancy until completion or until pregnancy 
termination and, in the case of a liveborn offspring, to 1 month of age of that infant and not ify 
BioPharmX of the outcome as a follow -up to the initial Pregnancy Form. All pregnancies should 
be reported to the sponsor and ethics committee.  
BioPharmX – Protocol BPX -01-C04- BPX-[ADDRESS_1078837] and each treatment group will be presented in tabular 
form.  
 
10.2.1  Analysis  Populations  
 
Efficacy will be evaluated on the basis of the intent -to-treat (ITT) population. A supportive 
analysis will also be conducted on the per -protocol (PP) population.  
 
All subjects who received at least one dose of the medication will be included in the ITT  
population. All subjects will be analyzed according to the treatment group to which they were 
assigned.  
 
The per -protocol (PP) population will include all subjects who were treated with no significant 
protocol deviations and who provided evaluable data fo r the primary endpoint (absolute change 
from baseline in inflammatory lesions count at Week 12).  
 
The safety population (SAF) will be defined as all subjects who received at least one dose of the 
medication. Analysis will be performed according to the actu al treatment they received.  
 
10.2.[ADDRESS_1078838] disposition will be  
presented. The protocol deviations will be summarized by [CONTACT_178467].  
 
10.2.3  Efficacy  Analysis  
 
[IP_ADDRESS]  Primary  Analysis  
 
Absolute change from baseline at Week [ADDRESS_1078839] atistically significant.  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 43 of 47  [IP_ADDRESS]  Secondary  and Exploratory  Analyses  
 
The secondary  and exploratory  efficacy  endpoints  will be presented  in tabular  form  and 
examined for trends.  
 
[IP_ADDRESS]  Safety  Analysis  
 
All safety data, including AEs and SAEs will be presented and tabulated according to type and 
body system classification. Descriptions of AEs will include the date of onset, the date the AE 
ended (if it resolved), the severity and seriousness of the AE, th e causality of the AE to study 
drug, and the outcome. The focus in this protocol will be the incidence of treatment emergent 
adverse events (TEAEs).  
 
Reported AEs will be summarized by [CONTACT_178459], as well as by 
[CONTACT_784366] , severity, seriousness, and relationship to study medication. For the summary of 
AEs by [CONTACT_926], each subject will be counted only once within a System Class or type by [CONTACT_784367]. For the summary of 
AEs by [CONTACT_92254], each subject will be counted only once within a System 
Class  or a type by [CONTACT_784368].  For 
the summary of AEs by [CONTACT_784369], each subject will be 
counted only once within a System Class or a type by [CONTACT_2329] (1) the greatest reported relationship 
followed by (2) the highest reported intensity.  
 
All information pe rtaining to AEs noted during the study will be listed by [CONTACT_1130], detailing 
verbatim, System Class, type, start date, stop date, intensity, outcome and relationship to study 
drug. The AE onset will also be shown relative (in number of days) to the day of t est article 
administration. Serious adverse events (SAEs) will be tabulated by [CONTACT_1570], relationship 
to the test article, and a reference to the occurrence of the SAEs to the relative day of dosing.  
 
Incidence of minocycline -induced skin hyperpi[INVESTIGATOR_53283], visual disturbances/headaches 
suggestive of pseudotumor cerebri, and product related staining will be summarized and 
presented descriptively by [CONTACT_1570].  
 
Concomitant  medications  will be listed  by [CONTACT_1130].  
 
In addition,  a list of subjects who  discontinued from  the study will  be provided.  
 
Shift tables describing shifts to clinically significant out of normal range will be provided for 
clinical laboratory results and normal -abnormal shift tables will be provided for vital signs.  
 
Local cutaneous tolerability scores will be tabulated by [CONTACT_646971].  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 44 of 47  10.2.4  Interim  Analysis  
 
No formal  interim  analysis  is planned  for this study.  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 45 of 47  11 DATA  QUALITY  ASSURANCE/SITE  MONITORNG  
During the study, BioPharmX or representatives will conduct monitoring visits at regular 
intervals. The monitoring visits will be conducted to ensure protocol adherence, quality of data, 
accuracy of entries on the CRFs, drug accountability, compliance with  regulatory requirements 
and continued adequacy of the investigational site and its facilities.  
 
The site may be audited and/or monitored by a quality assurance officer named by [CONTACT_131494]/or regulatory authorities may wish to perform on -site audits. The investigator will be given 
notice before an audit occurs and will be expected to cooperate with any audit, and provide 
assistance and documentation (including source data) as requested.  
 
[ADDRESS_1078840] assure that the subjects’ anonymity will be maintained and that their 
identities are protected from unauthorized parties. On CRFs or other documents, including 
photographs, submitted to  the sponsor, subjects should not be identified by [CONTACT_2249], but by  
[CONTACT_1209]. The investigator should keep a subject enrolment log relating codes with 
the names of subjects. The investigator should maintain documents not for submission to 
BioPharmX (e.g., subjects’ written consent forms) in strict confidence.  
 
14 INVESTIGATOR’S FILES AND RETENTION OF 
DOCUMENTS  
The investigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study da ta to be subsequently verified. These documents should 
be classified into two different separate categories: investigator study file and subject clinical 
source documents.  
 
The records should be retained by [CONTACT_784370] (ICH), local regulations, or as specified in the Clinical Trial Agreement (CTA), 
whichever is longer.  
 
15 ETHICS  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 46 of 47  15.1 Local  Regulations/Declaration  of Helsinki  
This study will be conducted in accordance with the ethical principles that have their origin in  
the Declaration of Helsinki (2008) and that are consistent with “Good Clinical Practice” ICH 
Tripartite Guideline (July 2002) and the applicable laws and regul ations of the country in which 
the research is conducted, whichever affords the greater protection to the individual.  
 
15.2 Ethical  Review  
It is the understanding of the sponsor that this protocol (and any amendments) as well as 
appropriate consent procedures, will be reviewed and approved by a research ethics board/ 
institutional review board (REB/IRB). This board must operate in accordance with the current 
federal regulations. For sites with local ethics committee, a letter or certification of approval will 
be sent by [CONTACT_569160], and also whenever 
subsequent modifications to the protocol are made.  
 
15.3 Informed  Consent  
It is the responsibility of the investigator, or a person designated by [CONTACT_093] (if  
acceptable by [CONTACT_1295]), to obtain written informed consent from each individual 
participating in this study, after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study. It must also be explained to the subjects that they are completely 
free to refuse to enter the study or to withdraw from it at any time for any reason.  
 
If new safety information results in significant changes in the risk/benefit assessment or any new 
information that may affect willingness to continue to participate, the consent form should if 
necessary be reviewed and updated by [CONTACT_941] (REB/IRB). All subjec ts (including those already 
being treated) should be informed of the new information, given a copy of the revised form and 
asked to give their consent to continue in the study.  
 
16 PUBLICATION  POLICY  
The publication policy will be addressed in the Research an d Financial agreement, and all details 
outlined in the agreement will apply to this protocol.  
BioPharmX – Protocol BPX -01-C04- BPX-01 Minocycline in Acne Vulgaris 
Protocol version 4.0 06 July 2017  
. 
Confidential  and proprietary.  Permission  should  be obtained  before  any reproduction.  Page 47 of 47  17 REFERENCES  
 
1. Leyden JJ. A review of the use of combination therapi[INVESTIGATOR_784355]. J Am Acad Dermatol. 2003;49([ADDRESS_1078841]):S200 -10. 
2. Bhate K, Williams HC. Epi[INVESTIGATOR_249592]. The British journal of 
dermatology. 2013;168:474 -85. 
3. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of 
acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad 
Dermatol. 2003;49([ADDRESS_1078842]):S1 -37. 
4. Weiss JS. Acne: evolving concepts of pathogenesis need to guide therapeu tic 
developments. J Drugs Dermatol. 2013; 12: s66.  
5. Minocycline  Topi[INVESTIGATOR_784356] -01, Investigator  Brochure,  BioPharmX,  January  25, 2016.  
6. Medicis,  Product  Information  of Solodyn  (minocycline  hydrochloride)  (2013).  
7. I. Chopra, M. Roberts, Tetracycline Antibioti cs: Mode of Action, Applications,  
Molecular Biology, and Epi[INVESTIGATOR_784357]. Microbiol. Mol. Biol.  
Rev. 2001; 65:232 –260. 
8. M. Jonas,  B. Cunha,  Minocycline.  Therapeutic  Drug  Monitoring.  1982;  4:137 –145. 
9. Food  and Drug  Administration  : Draft  guidance  on Acne  Vulgaris:  Developi[INVESTIGATOR_2862] (September 2005), Available from: 
http://www.fda.gov/downloads/drugs/guidan cecomplianceregulatoryinformation/guidanc  
es/ucm071292.pdf  
10. Yalcin I, Bump R. Validation of two global impression questionnaires for incontinence. 
Am J Obstet Gynecol. 2003;189:98 -101. 